NASDAQ:RARX - Ra Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $23.66 +0.32 (+1.37 %) (As of 05/26/2019 06:56 AM ET)Previous Close$23.66Today's Range$23.02 - $23.9652-Week Range$5.97 - $27.68Volume211,231 shsAverage Volume429,436 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/ABeta0.79 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts. Receive RARX News and Ratings via Email Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARX Previous Symbol CUSIPN/A CIK1481512 Webhttp://rapharma.com/ Phone617-401-4060Debt Debt-to-Equity Ratio0.02 Current Ratio20.10 Quick Ratio20.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.50 million Price / Sales400.36 Cash FlowN/A Price / Cash FlowN/A Book Value$4.52 per share Price / Book5.23Profitability EPS (Most Recent Fiscal Year)($2.06) Net Income$-64,940,000.00 Net MarginsN/A Return on Equity-47.05% Return on Assets-43.51%Miscellaneous Employees72 Outstanding Shares42,303,000Market Cap$1.00 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions What is Ra Pharmaceuticals' stock symbol? Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX." How were Ra Pharmaceuticals' earnings last quarter? Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.02. View Ra Pharmaceuticals' Earnings History. When is Ra Pharmaceuticals' next earnings date? Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Ra Pharmaceuticals. What price target have analysts set for RARX? 9 Wall Street analysts have issued 12-month price targets for Ra Pharmaceuticals' shares. Their forecasts range from $23.30 to $55.00. On average, they expect Ra Pharmaceuticals' share price to reach $38.70 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals. What is the consensus analysts' recommendation for Ra Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ra Pharmaceuticals. Has Ra Pharmaceuticals been receiving favorable news coverage? News stories about RARX stock have been trending positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of Ra Pharmaceuticals' key competitors? Some companies that are related to Ra Pharmaceuticals include Blueprint Medicines (BPMC), United Therapeutics (UTHR), Evotec (EVTCY), Alkermes (ALKS), ACADIA Pharmaceuticals (ACAD), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN) and Arena Pharmaceuticals (ARNA). What other stocks do shareholders of Ra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Zynerba Pharmaceuticals (ZYNE), Advanced Micro Devices (AMD), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Synergy Pharmaceuticals (SGYP), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Heron Therapeutics (HRTX) and Immunomedics (IMMU). Who are Ra Pharmaceuticals' key executives? Ra Pharmaceuticals' management team includes the folowing people: Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)Mr. David C. Lubner, Exec. VP & CFO (Age 55)Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of ResearchDr. Simon Read, Chief Scientific Officer (Age 48) When did Ra Pharmaceuticals IPO? (RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager. Who are Ra Pharmaceuticals' major shareholders? Ra Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (12.16%), BlackRock Inc. (7.51%), First Manhattan Co. (3.36%), Candriam Luxembourg S.C.A. (2.42%), FMR LLC (1.10%) and Dimensional Fund Advisors LP (0.89%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals. Which major investors are selling Ra Pharmaceuticals stock? RARX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Wellington Management Group LLP, Algert Global LLC, First Manhattan Co., Dimensional Fund Advisors LP, Emory University, Oxford Asset Management LLP and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Ra Pharmaceuticals. Which major investors are buying Ra Pharmaceuticals stock? RARX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Schonfeld Strategic Advisors LLC, Spark Investment Management LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Renaissance Technologies LLC, Federated Investors Inc. PA and Morgan Stanley. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals. How do I buy shares of Ra Pharmaceuticals? Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ra Pharmaceuticals' stock price today? One share of RARX stock can currently be purchased for approximately $23.66. How big of a company is Ra Pharmaceuticals? Ra Pharmaceuticals has a market capitalization of $1.00 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe. What is Ra Pharmaceuticals' official website? The official website for Ra Pharmaceuticals is http://rapharma.com/. How can I contact Ra Pharmaceuticals? Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected] MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 178 (Vote Underperform)Total Votes: 362MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Why is Cost of Capital Important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.